Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 04 - 25 tags : Positive save search
Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022
Published: 2022-04-25 (Crawled : 15:00) - biospace.com/
XAIR | $1.31 8.26% 7.63% 410K
|
Technology Services
|
| O: 0.86%
H: 19.86%
C: 11.06%
covid-19 air positive
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
Published: 2022-04-25 (Crawled : 14:20) - biospace.com/
NKTX | $7.16 -5.29% -5.59% 680K
|
Health Technology
|
| O: 88.03%
H: 0.0%
C: 0.0%
positive
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
Published: 2022-04-25 (Crawled : 14:20) - biospace.com/
AMTI 4 | $0.263 -14.3% -1.14% 0
|
Health Technology
|
| O: 3.76%
H: 1.07%
C: -2.13%
amt-101 trial positive results molecular topline phase 2
Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program
Published: 2022-04-25 (Crawled : 14:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: -0.94%
H: 6.04%
C: 5.41%
children program positive results publication phase 3 phase 2
Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
Published: 2022-04-25 (Crawled : 13:00) - biospace.com/
AYTU | $2.74 0.92% 0.91% 14K
|
Health Technology
|
| O: -2.45%
H: 10.0%
C: 3.17%
biopharma preclinical technology positive pre-clinical
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
Published: 2022-04-25 (Crawled : 12:00) - globenewswire.com
OCGN | News 4 | $1.17 -6.4% -6.84% 7.3M
|
Health Technology
|
| O: -1.25%
H: 6.33%
C: 4.64%
ocu400 trial positive
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Published: 2022-04-25 (Crawled : 06:00) - globenewswire.com
SYNH | $42.98 0.0% 7.4M
|
Health Services
|
| O: -8.39%
H: 1.73%
C: 0.48%
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
|
| O: 4.29%
H: 9.59%
C: 8.22%
treatment chmp positive
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.